Purple Biotech (PPBT) EPS (Basic) (2017 - 2026)

Purple Biotech (PPBT) has reported EPS (Basic) for 10 consecutive years, with -$2.69 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EPS (Basic) fell 140.65% year-over-year to -$2.69 in Q2 2026; TTM through Jun 2026 was $149.39, a 838.11% increase from a year earlier, with the FY2025 full-year figure at $160.93, up 264.45% from the prior year.
• EPS (Basic) was -$2.69 for Q2 2026 at Purple Biotech, down from $0.52 in the prior quarter.
• Over five years, EPS (Basic) peaked at $143.61 in Q4 2025 and troughed at -$2.69 in Q2 2026.
• A 5-year average of $37.66 and a median of $37.12 in 2022 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) soared 5642.93% in 2025 and plunged 140.65% in 2026, its largest moves.
• Over 5 years, EPS (Basic) stood at $66.49 in 2022, then tumbled by 34.39% to $43.63 in 2023, then tumbled by 94.27% to $2.5 in 2024, then soared by 5642.93% to $143.61 in 2025, then plunged by 101.87% to -$2.69 in 2026.
• The last three EPS (Basic) figures came in at -$2.69 (Q2 2026), $0.52 (Q1 2026), and $143.61 (Q4 2025), per Business Quant data.